Ben Doak

Head of Innovative Treatments • NHS England

Ben Doak is the Head of Innovative Treatments at NHS England.

Ben’s primary role is to fulfil NHS England’s commissioning responsibility to ensure that services are in place so patients can benefit from licensed ATMPs recommended by NICE (the National Institute of Health and Care Excellence) in the NHS in England.

Ben has worked in innovation through various roles in his career, including working with surgical innovations, overseeing the placement of innovations in treatment pathways through NICE clinical guidelines and streamlining commercial activity for new technologies in NHS England’s Commercial Medicines Directorate.

Since commencing his current role in 2020, Ben has overseen the expansion of CAR-T services in England as well as supporting access to ATMPs such as Zolgensma for spinal muscular atrophy, Libmeldy for metachromatic leukodystrophy and Upstaza for AADC deficiency. He maintains an active interest in horizon scanning of ATMPs and other innovative treatments.

Also speaking

Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Malik Kaman

Partner • ZS Consulting

Paula Pulsoni

Vice President, Sales and Services • World Courier

Event Info


Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.